New drug targets lung Cancer's fuel source after standard treatments fail
NCT ID NCT07249372
Summary
This study is testing an experimental drug called DRP-104 for people with a specific type of advanced non-small cell lung cancer that has continued to grow despite standard chemotherapy and immunotherapy. The drug works by blocking a nutrient called glutamine that some cancer cells need to survive. Researchers aim to see if this approach can shrink tumors and control the disease in 37 participants whose cancer has specific genetic changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
Contact
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.